Uveitis Treatment Market Size, Share, and Growth Forecast for 2025 - 2032

Uveitis Treatment Market Outlook (2025–2032)

The global revenue from the uveitis treatment market was around US$ 848.2 Mn in 2025, with the global market expected to grow at a CAGR of 7.3% to reach a valuation of around US$ 1,389.0 Mn by the end of 2032.

Market Size (2025)	US$ 848.2 Mn
Projected Market Value (2032)	US$ 1,389.0 Mn
Global Market Growth Rate (2025–2032)	7.3%  CAGR
Historical Market Growth Rate (CAGR 2019 to 2024)	6.9%

Sales Analysis of Market from 2019–2024 Vs Market Outlook for 2025–2032

The global market recorded a historic CAGR of 6.9% in the last 5 years from 2019–2024.

Controlling inflammation during uveitis treatment aims to minimise visual loss while also minimising adverse effects. Corticosteroids, cycloplegic drugs, immunosuppressant, monoclonal antibodies, antifungals, antibiotics, antivirals, and analgesics are some of the treatments for uveitis. Due to the rise in autoimmune illnesses worldwide, antibiotics used to treat uveitis are anticipated to experience the fastest growth during the projection period.

Due to its use as a first line treatment for uveitis, corticosteroids in the uveitis treatment type segment are the largest category in terms of revenue and are anticipated to maintain steady growth during the projected period. They are utilised in a variety of medication compositions, including prolonged release eye drops.

In developing countries like India, infection continues to be the predominant cause of uveitis. In contrast, idiopathic uveitis, an organ-specific immune inflammatory process, has been identified as the primary cause of the condition in affluent nations. Due to the rise in infectious illness frequency in developing nations, infectious uveitis accounts for significant revenue shares of more than 85% in the market. In 2024, anterior uveitis will account for around 57% of the market's overall revenues for uveitis treatment, with posterior uveitis coming in second.

The global market is likely to show high growth over the coming years at a CAGR of 7.3% and reach a global market size of US$ 1,389.0 Mn by 2032.

How Can the Global Market Grow?

“Rise in the Autoimmune Disorders and Increasing Eye Related”

There are many autoimmune illnesses, and the eye and other parts of the eye are among those that the white blood cells may target. This type of autoimmune disease makes a substantial contribution by frequently being systemic, which causes the illness to spread to numerous body organs. Intraocular inflammation is the hallmark of the sight-threatening condition known as autoimmune uveitis, which is frequently accompanied by systemic autoimmune diseases linked to Th17 cells, such as Behcet's illness.

• Uveitis is not always an organ-specific disorder, as stated in the article "Clinical link among dry eye disease and uveitis," a review in J Ophthal Inflamm Infect (2023). In reality, a systemic autoimmune illness is linked to non-infectious uveitis in up to 33% of instances. Yet research in the same study has revealed that in up to 53% of cases, these disorders can also be linked to changes in the ocular surface and DED.

Global market growth is being aided by an increase in eye problems. One of the numerous potentially catastrophic side effects of uveitis is glaucoma. Changes in aqueous production and composition, alterations in the morphology of the anterior chamber angle, and the effects of corticosteroid therapy all contribute to uveitis glaucoma.

• Glaucoma, for instance, is the second-most common cause of blindness worldwide. The WHO predicts that glaucoma will render 4.5 million people legally blind by the year 2020. At least 12 million individuals in India are affected with glaucoma, which leaves about 1.2 million of them legally blind. Glaucoma is the leading cause of lifelong blindness in India.

A large number of compounds are being developed for the treatment of uveitis. Leading players in the segment are working to expand their product portfolios with novel drugs. However, since the process for sterile formulations is extremely difficult, companies are inclining to align with GMP and regulatory guidelines in order to manufacture the upcoming products, which gives them extreme opportunities in the market.

Can the Market Growth Be Affected in Any Way?

“Complex Manufacturing Process Along with Limited First Line Drugs”

Patients are increasingly reporting side effects from uveitis medications such as irritability, wet eyes, and others. Given that there is less research on the effectiveness of the medications used to treat uveitis, these variables are increasingly posing significant challenges for healthcare practitioners and institutions. Further obstacles to the expansion of the uveitis treatment industry are the moderate prevalence and extremely restricted first-line medications.

To manufacture products that are properly aligned with Good Manufacturing Practice (GMP) rules for sterile products, eye care solutions for the treatment of uveitis require a special manufacturing procedure. As formulations are vulnerable to environmental pathogens, they are created in highly protected areas, which makes it difficult for manufacturers to meet the requirements outlined in GMP and other regulatory rules.

The market for uveitis treatments is also being hindered by inadequate basic medical care infrastructure, a lack of knowledge about eye problems, and a lack of medical coverage in underdeveloped countries.

Country–wise Insights

Why is the U.S. Market Booming?

"Rising Eye Related Disorders and Rising Awareness are Driving Growth of the Uveitis Treatment Market in the Country”

The U.S. accounted for around 26.9% market share in the global market in 2024.

• According to the Centers for Disease Control and Prevention, by 2022 there were more than 3.4 million people in United States aged 40 years or older who are blind or visually impaired. According to other estimates from the same source, there may be up to 21 million "vision difficulties," and 80 million people are thought to have eye conditions that could result in blindness. Cataracts, age-related macular degeneration, diabetic retinopathy, and glaucoma are the main causes of visual loss.

The awareness regarding eye disorders by American Academy of Ophthalmology and other departments are also aiding the market growth in the United States.

Will the U.K. Be a Lucrative Market for Uveitis Treatment?

"Government Support for the Integrated Care System for Eyes”

The United Kingdom market held around 7.1% share of the global market in 2024. Rising government support and increasing awareness by different organizations is adding value to the growth of the market.

• For instance, National Health Service (NHS) England has released guidance on eye care planning and implementation for 2023–2024. The recommendations emphasise several steps that can be taken to improve eye care, such as implementing standardised integrated care pathways spanning cataract, urgent eye care, medical retina, and glaucoma pathways; improving equity of access within and between ICSs; and reducing patient backlogs.

How is Canada Emerging as a Prominent Market?

“Growing Product Launches by Key Players”

Canada held a market share of about 6.5% of the global market in 2024.

• Idacio, a biosimilar to the injectable adalimumab product, was introduced in Canada in October 2021 by Fresenius Kabi, a German manufacturer. This medication is prescribed for a variety of conditions, including paediatric chronic noninfectious anterior uveitis and adult noninfectious uveitis.

The market is anticipated to hold the greatest share in the upcoming year due to superior healthcare services and the high number of individuals who suffer from eye infections in this region. Thus, the above mentioned factor is facilitating the market to grow.

Category–wise Insights

Which Treatment is More Adopted in the Global Market?

“Demand for Corticosteroids as First Line Treatment for”

The Corticosteroids held around 21.7% share of the total market in 2024.

The conventional of care for noninfectious uveitis is corticosteroids, which can be given topically, regionally, or systemic route of administration. The therapy of noninfectious uveitis now includes a range of regional corticosteroids. They include the intravitreal triamcinolone acetonide (Triesence, Alcon, Fort Worth, TX) formulation without preservatives.

• As per the paper "Practice practises associated with regional corticosteroid therapy in noninfectious uveitis: a survey study". In a survey published in Journal of Ophthalmic Inflammation and Infection. 2024, numerous participants (54.7%), who had unilateral uveitis, were willing to employ regional corticosteroids as first-line treatment.

Why Does Anterior Uveitis Have Such a Significant Market Share?

“Rising Conditions like Smoking and Rheumatologically Conditions”

Anterior Uveitis segment held around 57.6% share of the total market in 2024.

• According to a study published in journal of PLOS ONE 2020, anterior uveitis had the second-largest average prevalence rate (7.5 per 100,000) and maximum mean annual incidence of the anatomic categories of infectious uveitis (27.7 per 100,000)

The risk of developing infected anterior uveitis increased with age, education level, and location of the patient. Smoking and rheumatologic conditions are among a number of clinical comorbidities that have been strongly linked to an elevated risk of incident infected anterior uveitis.

Which Cause Has a Dominating Market Share in Uveitis Treatment?

“Infectious Uveitis Is Becoming More Common as The Risk of Toxoplasma Gondii Increases.”

Infectious uveitis holding around 87.2% share of the global market in 2024.

Infectious uveitis is one of the most common and visually debilitating causes of uveitis in the United States and around the world. The most common cause of infectious uveitis (56.1% of cases) was viral infection, followed by Toxoplasma gondii infection (24.5%).

Infection of the retinal pigment epithelium (RPE) results in the production of growth factors such as VEGF and thrombospondin-1, which stimulate the proliferation of adjacent uninfected cells. This causes the hyperpigmentation seen in OT and makes uninfected cells more vulnerable to infection.

Which Distribution Channel is Driving the Global Market?

“Accessible Services and Infrastructure Development of Hospital Pharmacies”

Hospital pharmacies held around 45.9% share of the total market in 2024.

There are prospects for market growth due to the increase in open angle glaucoma therapies provided by hospital pharmacists and the rise in the number of hospital patients in developed countries. In addition, because hospital pharmacies are conveniently located, patients prefer them for drug purchases. As a result, hospital pharmacies dominate the market's distribution channels.

Competition Landscape

There are many significant players in the fiercely competitive market for uveitis treatments. There are a sizable number of businesses that are embracing strategic initiatives including new product development, mergers and acquisitions, and regional expansion on a regular basis.

Some key instances of development include:

• ILUVIEN was launched in the Netherlands by Alimera Sciences Europe Ltd in December 2020. ILUVIEN is used to treat non-infectious uveitis affecting the posterior segment and diabetic macular edoema (DME) (NIPU). Geographical expansion is the launch strategy, making ILUVIEN accessible to more doctors and patients in more markets.
• As a public service, Tarsier Pharma, a pharmaceutical company in advanced clinical stages that focuses on the development and commercialization of novel therapeutics for blinding ocular diseases, launched a website in January 2024 called www.uveiticglaucoma.com with information about the illness known as uveitis glaucoma.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the Uveitis Treatment market, which are available in the full report.

Companies Covered in Uveitis Treatment Market

• Allergan, Inc
• Novartis AG
• Bausch Health Inc.
• AbbVie Inc.
• Tarsier Pharma
• EyeGate Pharmaceuticals, Inc.
• Alimera Science Inc,
• Eyepoint Pharmaceutical
• Santen Pharmaceuticals